贝达药业：公司推进BPI-572270项目的临床申报工作

Core Viewpoint - The company, Betta Pharmaceuticals (300558), is committed to complying with legal regulations and exchange rules regarding disclosure obligations, particularly concerning the clinical application of the BPI-572270 project [1] Group 1 - The company has stated that it will timely fulfill its disclosure obligations regarding any significant developments in the BPI-572270 project [1] - The clinical application for the BPI-572270 project is currently under review [1] - The completed work milestones for the project do not fall under the statutory disclosure timelines [1]